ExploreWatchlistsPricing
  1. JP-listed companies
  2. SEIKAGAKU CORPORATION
  3. Financials
  4. Cash and cash equivalents

SEIKAGAKU CORPORATION (4548)

Market cap
¥44.5B
P/E ratio
19x
Develops and manufactures pharmaceuticals for joint care, eye surgery, and spinal treatments, plus specialized LAL testing reagents that ensure drug safety.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Mar 31, 20268,938-40.93%
Mar 31, 202515,132-1.99%
Mar 31, 202415,439-34.16%
Mar 31, 202323,451+8.98%
Mar 31, 202221,518+41.64%
Mar 31, 202115,192+15.97%
Mar 31, 202013,100+45.77%
Mar 31, 20198,987+25.89%
Mar 31, 20187,139-2.22%
Mar 31, 20177,301-2.80%
Mar 31, 20167,511-12.41%
Mar 31, 20158,575

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat